➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Merck
Baxter
Dow

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AZD9291

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AZD9291?

AZD9291 is an investigational drug.

There have been 64 clinical trials for AZD9291. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.

There are eighteen US patents protecting this investigational drug and two hundred and sixty international patents.

Recent Clinical Trials for AZD9291
TitleSponsorPhase
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerAstraZenecaPhase 3
AZD9291 (Osimertinib) With or Without Bevacizumab as First-Treatment for Patients With EGFR-Mutant Lung CancerNational Cancer Institute (NCI)Phase 3
Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1

See all AZD9291 clinical trials

Clinical Trial Summary for AZD9291

Top disease conditions for AZD9291
Top clinical trial sponsors for AZD9291

See all AZD9291 clinical trials

US Patents for AZD9291

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD9291   Start Trial 2-(2,4,5-substituted-anilino)pyrimidine compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD9291   Start Trial AZD9291 intermediate and preparation method therefor SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN)   Start Trial
AZD9291   Start Trial Pharmaceutical compositions comprising AZD9291 AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD9291   Start Trial Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
AZD9291   Start Trial Pyrimidines as EGFR inhibitors and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
AZD9291   Start Trial Acrylanilide derivative, preparation method, and applications thereof in pharmacy Ancureall Pharmaceutical (Shanghai) Co., Ltd. (Shanghai, CN)   Start Trial
AZD9291   Start Trial Inhibitors of EGFR and methods of use thereof Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD9291

Drugname Country Document Number Estimated Expiration Related US Patent
AZD9291 Argentina 087336 2031-07-27   Start Trial
AZD9291 Australia 2012288626 2031-07-27   Start Trial
AZD9291 Brazil 112014001768 2031-07-27   Start Trial
AZD9291 Brazil 122014026094 2031-07-27   Start Trial
AZD9291 Brazil 122014026114 2031-07-27   Start Trial
AZD9291 Brazil 122014026150 2031-07-27   Start Trial
AZD9291 Canada 2843109 2031-07-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Merck
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.